Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 9/20 | 0.32 |
| ▸ | AURKA | O14965 | 5/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26675400 | 1.00 | PDPK1 (0.32) | PDPK1AURKATGFBR1AURKBROCK1 | |
| SCHEMBL26675403 | 0.84 | PDPK1 (0.33) | PDPK1AURKATGFBR1AURKBROCK1 | |
| SCHEMBL26834939 | 0.84 | PDPK1 (0.33) | PDPK1AURKATGFBR1AURKBROCK1 | |
| SCHEMBL26675371 | 0.83 | AURKA (0.30) | PDPK1AURKATGFBR1AURKBROCK1 | |
| SCHEMBL26675350 | 0.78 | ILK (0.38) | PDPK1AURKATGFBR1AURKBROCK1 | |
| SCHEMBL26835001 | 0.78 | TRPV3 (0.37) | PDPK1AURKATGFBR1AURKBROCK1 | |
| SCHEMBL26675353 | 0.76 | AOC3 (0.32) | PDPK1AURKATGFBR1AURKBROCK1 | |
| SCHEMBL26834986 | 0.76 | PDPK1 (0.36) | PDPK1AURKATGFBR1AURKBROCK1 | |
| SCHEMBL26675440 | 0.75 | PDPK1 (0.38) | PDPK1AURKATGFBR1AURKBROCK1 | |
| SCHEMBL26675448 | 0.75 | PDPK1 (0.40) | PDPK1AURKATGFBR1AURKBROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382911-A1 | PYRAZOLEAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382911-A1 | PYRAZOLEAMIDE DERIVATIVES | P2RY1, P2RX1, P2RX5 | PDPK1 1700/4885AURKA 2686/4885TGFBR1 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.